Prognostic Stage IV Breast Cancer AJCC v8 Not Yet Recruiting Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0109667 (Prognostic Stage IV Breast Cancer AJCC v8)Not Yet Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT06324240Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast CancerTreatment